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Original Article
randomized clinical trials failed to show the superior-
ity of the use of distal protection (DP) devices4-6), 
although DP devices were considered to be effective in 
preventing distal embolization, particularly in experi-
mental studies7). One of the reasons for these contro-
versies may be explained by the fact that previous DP 
devices, such as balloon occlusion type, needed to 
interrupt coronary blood flow and, even under these 
conditions, resulted in incomplete protection of distal 
embolization4, 8).
During the collection of materials that provoke 
distal embolization, filter-type DP devices7, 9, 10) such 
as Filtrap® (Nipro Corporation, Tokyo, Japan) did not 
interrupt coronary flow in infarct-related vessels and 
Introduction
It is evident that the occurrence of distal emboli-
zation and the associated slow-flow/no-reflow phenom-
enon after percutaneous coronary intervention (PCI) 
for acute myocardial infarction (AMI) result in poor 
prognoses1-3). However, under these conditions, some 
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dardized distal landmark was counted17). Frames were 
counted by using images acquired at 30 frames per 
second with the 6Fr size of the catheter.
The Basic Principle of Filtrap® (NIPRO, Japan)
Details of Filtrap® have already been described 
elsewhere9, 15). In brief, the filter is attached to the dis-
tal end of a 0.014-inch guidewire. The filter mem-
brane is attached to half of the filter basket. The filter 
membrane is made of polyurethane and has approxi-
mately 1800 holes. Each hole size is approximately 
100 µm, and the membrane is 40 µm thick (Fig.1A).
Intravascular Ultrasound
IVUS (Eagle Eye Gold 2.9-F 20 MHz, Volcano 
Corporation, Rancho Cordova, USA) was performed 
before and after each procedure. IVUS images were 
recorded using a motorized transducer pull back sys-
tem (0.5 m/s). IVUS studies were recorded and mea-
sured using computerized planimetry18, 19). We evalu-
ated the sections with the smallest luminal cross-sec-
tional area, distal reference, and proximal reference. 
The reference site was selected as the most visually 
normal section with the largest lumen and smallest 
plaque cross-sectional area within 10 mm proximal to 
the target lesion. The total vessel area was measured by 
tracing the outer border of the external elastic mem-
brane (EEM), and the lumen area was measured by 
tracing the interface between the vessel lumen and 
leading edge of the initial echogenic layer. The plaque 
area was calculated as the difference between the vessel 
area and lumen area.
Plaque burden was defined as plaque area divided 
by the EEM cross-sectional area20). The remodeling 
index was the ratio of lesion site EEM cross-sectional 
area divided by the average of the proximal and distal 
needed less complicated procedures than previous DP 
devices. Indeed, experimental studies demonstrated that 
Filtrap® effectively protects distal coronary flow, pre-
serving myocardial function after ischemia7). However, 
limited clinical data exists regarding filter-type DP 
devices, which are considered to be gentle to the coro-
nary artery11). Therefore, the aim of this study was to 
investigate whether Filtrap® could improve reperfusion 
in primary PCI and to reveal long term outcomes.
Methods
Study Population
The study protocol was approved by the Bioethi-
cal Committee on Medical Research, Ishikawa Prefec-
tural Central Hospital. Written informed consent for 
procedures was obtained from all patients before PCI. 
Between January 2007 and August 2010, 182 consec-
utive AMI patients (142 men, mean age: 66.1 years) 
who underwent emergent coronary interventions at 
our institutes were enrolled in this study. Of these, we 
examined 164 AMI patients (130 men, mean age: 65.7 
years) who underwent intravascular ultrasound (IVUS) 
guided primary PCI. The remaining 18 patients had 
delivery failure of the Filtrap® device (n?12), a lesion 
at the bypass graft (n?2), and stent thrombosis after 
PCI procedures (n?4) and were thus excluded.
Procedures
All patients were pre-medicated with 200 mg of 
aspirin and received 8000 IU of heparin in a bolus 
injection. In addition, all patients were prescribed a 
loading dose of clopidogrel or ticlopidine after inter-
vention. PCI was performed according to the standard 
clinical techniques with radial or femoral artery 
approaches using a 6Fr guiding catheter after intracor-
onary administration of isosorbide dinitrate. Culprit 
lesions were classified according to the AHA/ACC 
classification12). Intra-arterial flow was graded as 0–3 
according to the Thrombolysis in Myocardial Infarc-
tion trial (TIMI) classification13-15). Collateral flow 
was graded according to Rentrop’s score16). After pas-
sage of a 0.014-inch guidewire across the lesion, we 
performed a thrombus aspiration procedure to remove 
intracoronary thrombus by the aspiration device as 
much as possible. Then, we evaluated IVUS findings. 
If the IVUS catheter failed to deliver because of severe 
organic stenosis or calcification, dilatation by a small 
balloon (?2.5 mm) was added. According to the IVUS 
findings and angiographic information, the operator 
decided whether to deploy Filtrap® or not15). Then, 
we implanted a drug-eluting or bare metal stent. In 
the corrected TIMI frame count (CTFC) method, the 
number of frames required for the dye to reach a stan-
Fig.1. View of the filter basket and internal side of the filter 
membrane of Filtrap® (NIPRO, Japan). A: Unused 
device, B: Membrane with the case of transient filter 
no-reflow. Note: a large amount of debris was observed.
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related leads on the baseline ECGs and from the same 
leads on the post-PCI ECGs to analyze ST resolution 
in the ST elevation myocardial infarction cases. The 
percentage of ST resolution from the baseline to 60 
min after the procedure was calculated. We defined an 
ST resolution ?70% as complete ST resolution10). 
Follow-up data were obtained from hospital charts 
and information from patients’ general physicians as 
well as by a direct interview or a telephone interview 
with patients or one of their close relatives.
Statistical Analysis
SPSS version 21.0 (SPSS Inc., Chicago, IL) was 
used for all analyses. Categorical data were expressed 
as absolute frequencies and percentages and were com-
pared using a Chi square test or Fisher’s exact test, as 
appropriate. Continuous variables, which were expressed 
as the mean?standard deviation (SD), were compared 
using either an unpaired Student’s t -test or the Mann–
Whitney U test. Cumulative incidences were estimated 
using the Kaplan–Meier method, and differences were 
assessed with the log-rank test. Multiple logistic regres-
sion analysis was used to determine the independent 
predictors for outcomes. A p value of ?0.05 was con-
sidered statistically significant.
reference EEM cross-sectional areas21, 22).
Study Outcomes
We divided 164 patients into two groups based 
on the use of Filtrap®. Angiogram, IVUS findings, 
CTFC, ST resolution, and peak CK levels were com-
pared between both the groups. We evaluated the inci-
dence of major adverse cardiac events (MACE) defined 
as cardiac death, recurrent acute myocardial infarction, 
and ischemia-driven target vessel revascularization 
(TVR) during a 2-year follow-up. We also evaluated 
the incidence of congestive heart failure (CHF) and 
malignant arrhythmia during a 2-year follow-up. CHF 
was defined as New York Heart Association Class ? 
or ? requiring intra-venous medication (including 
diuretics, vasodilators, or inotropic agents) for objec-
tive evidence of congestion or left ventricular dysfunc-
tion. In addition, we evaluated the incidence of hospi-
talization due to a worsening of CHF during a 2-year 
follow-up. Malignant arrhythmia included sustained 
ventricular tachycardia and ventricular fibrillation.
ECG was performed when patients were admit-
ted to the hospital and at 60 min after reperfusion. 
The QRS score was defined as the sum of QRS volt-
ages in all 12 leads on the basis of a previous study23). 
ST-segment elevation was summed from all the infarct-































































































Continuous data are presented as mean?standard deviation; categorical data are presented as a number (%)
?p?0.05 indicates that the DP group is significantly different from the non-DP group.
DP distal protection, BMI body mass index, MI myocardial infarction, eGFR estimated glemerular filtration rate, LVEF left ventricular ejection 
fraction, STEMI ST elevation myocardial infarction, NSTEMI non-ST elevation myocardial infarction
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group than in the non-DP group (19.2?5.3 mm2 vs. 
17.0?4.6 mm2, p?0.01). The relations were similar 
in the EEM cross-sectional area of the distal reference 
site (16.5?4.6 mm2 vs. 13.1?5.1 mm2, p?0.01) and 
of the lesion site (19.8?5.7 mm2 vs. 16.1?4.7 mm2, 
p?0.01). Although pre-procedural IVUS imaging 
demonstrated significantly greater plaque area in the 
DP group than in the non-DP group (16.7?5.7 mm2 
vs. 13.2?4.6 mm2, p?0.01), plaque burden was 
equivalent in both the groups (83.1?6.9% vs. 81.5?
6.1%, p?0.21).
Outcomes
Table 3 shows the TIMI flow grade before and 
after PCI. Overall, TIMI flow grade clearly improved 
after PCI. Although there were no significant differ-
ences in TIMI flow grade 3 and CTFC after PCI 
between both the groups, the incidence of TIMI flow 
grade 0-1 after PCI was significantly lower in the DP 
Results
Baseline Demographics and Lesion Characteristics
DP was performed in 53 patients, but not in 111 
patients (Table 1). Although there were no significant 
differences in patients’ basic background between both 
the groups, patients in the DP group showed lower 
systolic blood pressure and lower heart rate at admis-
sion than those in the non-DP group. In addition, the 
DP group had a higher incidence of Killip class ? or 
?. The QRS score was lower in the DP group than in 
the non-DP group. As for pre-procedural angiographic 
characteristics, Filtrap® was more frequently used for 
RCA lesions than for LAD or LCX lesions. The DP 
group received more sufficient collateral artery than 
the non-DP group (Table 2).
Pre-procedural IVUS findings are shown in 
Table 2. The EEM cross-sectional area in the proxi-
mal reference site was significantly greater in the DP 














































































































Continuous data are presented as mean?standard deviation; categorical data are presented as a number (%)
?p?0.05 indicates that the DP group is significantly different from the non-DP group.
LMT left main trunk, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, NS not significant, EEM 
external elastic membrane, CSA cross-sectional area
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Fig.3 shows the results of the detailed sub-analy-
sis of the relationships between peak CK level in the 
acute phase and CHF during the 2-year follow-up. 
On the whole, patients with CHF (n?27) showed 
higher CK levels than those without CHF (n?137) 
(5154?4516 IU/L vs. 2786?1925 IU/L, p?0.012). 
In the DP group, the CK level was not different in 
patients with or without CHF (2298?1672 IU/L vs. 
3281?2187 IU/L, p?0.449). However, in the non-DP 
group, the CK level was significantly higher in patients 
with CHF than in those without CHF (5511?4649 
IU/L vs. 2502?1707 IU/L, p?0.005) with a back-
ground of lower LVEF in patients with CHF than in 
those without CHF (41.7% vs. 50.8%, p?0.01). 
Despite this underlying bias in cardiac function, DP 
usage and LVEF predicted CHF independently (Table 
4). Interestingly, patients with CHF after the non-DP 
procedure exhibited a higher CK level than that in 
patients with CHF after the DP procedure (p?0.049), 
group than in the non-DP group. ST resolution and 
peak CK level were not different in both the groups 
(Table 5).
In multivariate logistic regression analysis, diabe-
tes mellitus and Killip class ? or ? predicted MACE 
independently (Table 4). The use of DP device did 
not predict MACE independently. Meanwhile, age, 
LVEF, DP device usage, and peak CK were indepen-
dent predictors of CHF following multivariate analy-
sis (Table 4).
There was no significant difference in the inci-
dence of MACE up to a 2-year follow-up between the 
two groups (p?0.21). Interestingly, the incidence of 
CHF was significantly higher in the non-DP group 
than in the DP group (21.6% vs. 5.7%, p?0.01) 
(Table 5). Importantly, the cumulative incidence of 
CHF over 2 years was significantly lower in the DP 
group than in the non-DP group (log-rank p?0.018) 
(Fig.2).
















































Continuous data are presented as mean?standard deviation; categorical data are presented as a number (%)
?p?0.05 indicates that the DP group is significantly different from the non-DP group.
TIMI thrombolysis in myocardial infarction
Table 4. Multivariate logistic regression analysis of baseline variables, procedural findings in predicting CHF and MACE































plaque at the lesion was greater in the DP group than 
in the non-DP group. Therefore, it was possible that 
the DP group could have a worse prognosis. From this 
point of view, use of Filtrap® preserved myocardial 
perfusion and resulted in less CHF compared with the 
non-DP group.
Causes of the no-reflow phenomenon are consid-
ered to be multifactorial. There are four considerable 
pathogenic mechanisms of the no-reflow phenome-
non: 1) distal atherothrombotic embolization28), 2) 
ischemic injury, 3) reperfusion injury, and 4) suscepti-
bility of coronary microcirculation to injury29). Large 
emboli (?200 µm in diameter) can obstruct pre-arte-
rioles, and thrombus formation may be associated with 
inadequate antiplatelet effects of clopidogrel, which is 
related to cytochrome P450 2C19 polymorphisms30). 
Ischemic injury, which is caused by reduced regional 
myocardial blood flow, causes endothelial protrusions, 
interstitial edema, and myocardial cell swelling. Fil-
trap® cannot prevent all these factors, but one positive 
effect is thought to be its ability to trap most emboli-
zation (Fig.1B). Indeed, filter slow-flow/no-reflow, 
which suggests the capture of sufficient debris, was 
found in the DP group, as was also observed in our 
present study15).
In the association between outcomes and Filtrap® 
usage, the frequency of CHF was significantly lower 
in the DP group than in the non-DP group (5.7% vs. 
21.6%, p?0.01). This difference was found at an early 
stage after PCI. Interestingly, multivariate regression 
analysis showed that Filtrap® usage was one of the 
independent predictors of CHF (Table 4). It is possi-
ble that there could be considerable myocardial necro-
sis in patients with CHF because they exhibited higher 
peak CK levels than patients without CHF. In addi-
tion, the CK level of patients with CHF in the non-
DP group was significantly higher than those with 
even with a background of similar LVEF between the 
two groups (39.4% vs. 41.7%, p?0.721).
Discussion
The two main findings of this study are summa-
rized further. Firstly, Filtrap® usage was an indepen-
dent predictor for the CHF-free status of patients, and 
the long-term CHF rate was significantly lower in the 
DP group than in the non-DP group during the 
2-year follow-up. Secondly, although there were no 
differences in CK levels between the DP and non-DP 
groups, a DP procedure may induce lower CK levels 
than a non-DP procedure in particular cases of CHF.
Several studies have suggested that pre-stenting 
IVUS findings are associated with the occurrence of 
the angiographic slow-flow/no-reflow phenomenon 
during PCI in patients with AMI19, 24-27). Tanaka et al 
reported that a lesion EEM cross-sectional area (p?
0.05; odds ratio: 1.55; 95% CI: 1.01 –2.38) served as 
an independent predictive factor of the no-reflow phe-
nomenon after reperfusion for AMI26). Another study 
noted that the vessel area and plaque area in the cul-
prit lesion in patients in which transient no-reflow 
occurred during PCI were significantly greater than in 
patients without no-reflow27). Thus, in this study, the 
risk of slow-flow/no-reflow was higher in the DP group 
than in the non-DP group because the DP group had 
greater EEM and plaque area than the non-DP group.
Although CTFC in the final angiogram was not 
different in both the groups, Filtrap® usage successfully 
and significantly reduced the incidence of the most 
serious TIMI 0-1 (Table 3). In this study, there was no 
significant difference in the MACE rate up until the 
2-year follow-up between both the groups. Although 
there was no difference in plaque burden at the lesion 
site between both the groups, the absolute quantity of 

















































Continuous data are presented as mean?standard deviation; categorical data are presented as a number (%)
?p?0.05 indicates that the DP group is significantly different from the non-DP group.
MACE major adverse cardiac events, VF ventricular fibrillation, VT ventricular tachycardia, CHF congestive heart failure
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infarct-related coronary artery than patients without 
CHF in the DP group (n?50) (reference diameter: 
2.85 mm vs. 3.35 mm, p?0.01; plaque area: 13.0 
mm2 vs. 16.5 mm2, p?0.01). We have inferred that 
small vessels and plaques could have contributed to a 
numerically low CK level in patients without CHF, 
even without usage of the DP device.
CHF in the DP group, whereas the CK level was simi-
lar among patients without CHF regardless of DP 
(Fig.3). There could be a considerable mechanism for 
difference in the protective effect of the DP device 
between patients with CHF and those without CHF, 
as follow: patients without CHF in the non-DP group 
(n?87) had smaller vessels and less plaque areas in the 
Fig.2. Kaplan-Meier curves of the clinical outcomes during a two-year follow-up in 
patients treated with or without Filtrap®. A: The cumulative occurrence of CHF 
was significantly lower in the DP group than in the non-DP group (3.8% vs. 
17.1%, log-rank p?0.018). B: The cumulative occurrence of MACE was similar 
in 2 groups (26.4% vs. 18.9%, log-rank p?0.238).





































This study has several potential limitations. First, 
this study was a retrospective single-center experience 
in a limited number of patients. However, even under 
these conditions, the use of Filtrap® exhibited a pref-
erable outcome, particularly in patients with CHF. 
Second, the clinical backgrounds, such as the artery 
involved, the hemodynamic state before PCI, Killip 
class, and the QRS score, were different between both 
the groups, thus indicating that several undefined 
biases may have influenced the outcome. Meanwhile, 
DP usage was still an independent predictor for CHF 
after adjustment of these factors. Third, incomplete 
embolic protection may have occurred because of the 
limited size of Filtrap®, although all patients in the DP 
group were angiographically considered to be adapted.
Several studies describing the use of DP devices 
during primary PCI have shown heterogeneous results 
probably because of different population subsets, a 
variety of surrogate endpoints, and differences in the 
protection device technology used31-34). Recent clinical 
trials that examined distal filter-type devices, which 
were structurally different from Filtrap®, failed to dem-
onstrate an improved clinical outcome in patients with 
AMI35, 36). Filtrap® has a spindle-shaped spiral Ni–Ti 
wire basket. This unique self-expandable structure, 
which gently attaches to the vessel wall, may effi-
ciently retrieve thrombosis and is less invasive than 
previous products. There were no complications when 
Filtrap® was used in our study. The procedure is rela-
tively easy and can be performed in a short period of 
time, supported by Filtrap®, which is useful for pri-
mary PCI with AMI patients. Further investigation is 
warranted to elucidate the efficacy of the filter-based 
DP device Filtrap® on selected high risk patients with 
distal embolization.
Fig.3. Comparison of peak CK level after PCI in patients with or without congestive heart failure (CHF) during 
a two-year follow-up. On the whole, patients with CHF (n?27) showed higher CK levels than those 
without CHF (n?137) (5154?4516 IU/L vs. 2786?1925 IU/L, p?0.012). In the DP group, the CK 
level was not different in patients with or without CHF (2298?1672 IU/L vs. 3281?2187 IU/L, 
p?0.449). In the non-DP group, the CK level was significantly higher in the patients with CHF than 
those without CHF (5511?4649 IU/L vs. 2502?1707 IU/L, p?0.005). Note that the patients with 
CHF in the non-DP group exhibited higher CK levels than in patients with CHF after the DP procedure 
(5511?4649 IU/L vs. 2298?1672 IU/L, p?0.049).
CHF congestive heart failure
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1321
mechanical revascularization for acute myocardial infarc-
tion: a meta-analysis of randomized trials. Am Heart J. 
2007; 153: 343-353
7) Watanabe S, Saito N, Tokushige A, Bingyuan B, Kawase 
Y, Kimura T. A novel method to deliver the Filtrap coro-
nary embolic protection filter using a manual thrombec-
tomy catheter: in vitro and in vivo comparison with the 
conventional method. J Invasive Cardiol. 2012; 24: 159-
163
8) Muramatsu T, Kozuma K, Tsukahara R, Ito Y, Fujita N, 
Suwa S, Koyama S, Saitoh M, Kamiya H, Nakamura M; 
ASPARAGUS Trial Investigators. Comparison of myocar-
dial perfusion by distal protection before and after pri-
mary stenting for acute myocardial infarction: angio-
graphic and clinical results of a randomized controlled 
trial. Catheter Cardiovasc Interv. 2007; 70: 677-682
9) Isshiki T, Kozuma K, Kyono H, Suzuki N, Yokoyama N, 
Yamamoto Y. Initial clinical experience with distal embolic 
protection using “Filtrap”, a novel filter device with a self-
expandable spiral basket in patients undergoing percutan-
eous coronary intervention. Cardiovasc Interv Ther. 2011; 
26: 12-17
10) Ito N, Nanto S, Doi Y, Kurozumi Y, Tonomura D, Natsu-
kawa T, Sawano H, Masuda D, Yamashita S, Okada K, 
Hayashi Y, Kai T, Hayashi T. Distal protection during pri-
mary coronary intervention can preserve the index of 
microcirculatory resistance in patients with acute anterior 
ST-segment elevation myocardial infarction. Circ J. 2011; 
75: 94-98
11) Teramoto R, Miwa K, Matsubara T, Yasuda T, Inoue M, 
Okada H, Yakuta Y, Matsui T, Kanaya H, Yamagishi M. 
Efficacy of Distal Protection Device on Correlates of 
Adverse Events in Patients with Acute Myocardial Infarc-
tion. Circulation. 2012; 126: A14077
12) Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes 
D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams 
DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster 
V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr; 
American College of Cardiology/American Heart Associa-
tion task force on practice guidelines (Committee to revise 
the 1993 guidelines for percutaneous transluminal coro-
nary angioplasty); Society for Cardiac Angiography and 
Interventions. ACC/AHA Guidelines for Percutan eous 
Coronary Intervention (Revision of the 1993 PTCA 
Guidelines)--Executive Summary: A Report of the Ameri-
can College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (Committee to Revise 
the 1993 Guidelines for Percutaneous Transluminal Coro-
nary Angioplasty) Endorsed by the Society for Cardiac 
Angiography and Interventions. Circulation. 2001; 103: 
3019-3041
13) The Thrombolysis in Myocardial Infarction (TIMI) trial. 
Phase ? findings. TIMI Study Group. The Thrombolysis 
in Myocardial Infarction (TIMI) trial. Phase I findings. N 
Engl J Med. 1985; 312: 932-936
14) Sakata K, Kawashiri MA, Ino H, Matsubara T, Uno Y, 
Yasuda T, Miwa K, Kanaya H, Yamagishi M. Intravascular 
ultrasound appearance of scattered necrotic core as an 
index for deterioration of coronary flow during interven-
tion in acute coronary syndrome. Heart Vessels. 2012; 27: 
443-452
Conclusion
This study demonstrated the possible ability of 
Filtrap® to prevent CHF in AMI patients.
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